U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06811012) titled 'Phase II Clinical Study of Contezolid for the Treatment of Bone and Joint Tuberculosis' on Jan. 31.
Brief Summary: Contezolid is a novel oxazolidinone antibacterial agent that has shown promising application prospects in the field of tuberculosis treatment in recent years. Studies have demonstrated that contezolid exhibits comparable anti-tuberculosis activity to linezolid both in vitro and in vivo, and even superior intracellular bactericidal activity against Mycobacterium tuberculosis. More importantly, contezolid significantly reduces the risks of bone marrow suppression toxicity, neurotoxicity, and lactic acidosis compared to lin...